Healthcare · Biotechnology
Price
$24.92
Market Cap
$186.3M
Employees
42
Beta
0.51
Avg Volume
131,888
CEO
Craig Parker
Business Description
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Business History
Price Overview
Price at report time · Jul 5, 4:11am (0m ago)
$24.92
Change · Jul 5
-0.60 (-2.35%)
Day Range
$24.74 – $26.30
52-Week Range
$8.08 – $35.00
50-Day MA
$26.88
200-Day MA
$21.91
Volume
98,726.00
Right now · live
loading…
Real-time — the change above is the move since the report (over 0m).
Analyst Price Targets
Low
$40.00
Consensus
$42.00
High
$44.00
(4 analysts)
Share Structure
Outstanding
7,477,419.00
Float
3,273,629.00
Free Float
43.8%
Moderate free float
— 43.8% of shares trade freely, ~56.2% held by insiders/institutions
Reasonable but insiders still hold a significant stake. This can be positive (skin in the game) but may limit liquidity during sell-offs.
Small absolute float (3.3M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.77
Stock Price: $24.92
EPS (Diluted): -32.37
EPS (Diluted): -32.37
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-0.90
Stock Price: $24.92
Total Equity: -$187.76M
Shares: 7,478,000
Total Equity: -$187.76M
Shares: 7,478,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.25
Market Cap: $186.34M
Total Debt: $0.00
Cash: $89.25M
EBITDA: -$241.49M
Total Debt: $0.00
Cash: $89.25M
EBITDA: -$241.49M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$86.4M
Market Cap: $186.34M
Total Debt: $0.00
Cash: $89.25M
Total Debt: $0.00
Cash: $89.25M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
48.61
Stock Price: $24.92
Revenue: $3.48M
Shares: 7,478,000
Revenue: $3.48M
Shares: 7,478,000
EV/Sales (Total value vs revenue — works when P/E can't)
API24.85
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
84.6%
Gross Profit: $2.94M
Revenue: $3.48M
Revenue: $3.48M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-1,210.6%
Operating Income: -$42.09M
Revenue: $3.48M
Revenue: $3.48M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-6,960.8%
Net Income: -$242.03M
Revenue: $3.48M
Revenue: $3.48M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
309.8%
Net Income: -$242.03M
Total Equity: -$187.76M
Total Equity: -$187.76M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-38.0%
Operating Income: -$42.09M
Tax Rate: 0.0%
Equity: -$187.76M
Total Debt: $0.00
Cash: $89.25M
Tax Rate: 0.0%
Equity: -$187.76M
Total Debt: $0.00
Cash: $89.25M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
9.22
Current Assets: $91.56M
Current Liabilities: $9.93M
Current Liabilities: $9.93M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: -$187.76M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: -$187.76M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.46
Revenue: $3.48M
Shares: 7,478,000
Shares: 7,478,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-25.11
Total Equity: -$187.76M
Shares: 7,478,000
Shares: 7,478,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-4.06
Operating CF: -$30.24M
CapEx: -$128,000
Shares: 7,478,000
CapEx: -$128,000
Shares: 7,478,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $24.92
Stock Price: $24.92
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$242.03M
Net Income: -$242.03M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares SRZN against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 5, 2026 4:11am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $12.5M | $0 | $10.7M | $3.5M |
| Cost of Revenue | $3.3M | $3.3M | $27.2M | $0 | $537,000 |
| Gross Profit | -$3.3M | $9.2M | -$27.2M | $10.7M | $2.9M |
| Operating Expenses | $51.1M | $53.6M | $18.6M | $36.2M | $45.0M |
| Operating Income | -$54.4M | -$44.3M | -$45.8M | -$25.5M | -$42.1M |
| Net Income | -$52.5M | -$36.0M | -$43.0M | -$63.6M | -$242.0M |
| EBITDA | -$51.4M | -$34.0M | -$41.1M | -$62.1M | -$241.5M |
| EPS | $-23.40 | $-15.55 | $-21.33 | $-21.67 | $-32.37 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 5, 2026 4:11am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $33.1M | $24.7M | $36.0M | $34.6M | $89.2M |
| Total Current Assets | $105.2M | $81.3M | $41.1M | $38.9M | $91.6M |
| Total Assets | $137.2M | $89.4M | $46.1M | $48.5M | $98.7M |
| Current Liabilities | $13.6M | $9.7M | $7.1M | $7.3M | $9.9M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $27.5M | $13.4M | $8.1M | $69.8M | $286.5M |
| Total Equity | $109.7M | $76.0M | $37.9M | -$21.4M | -$187.8M |
| Retained Earnings | -$142.6M | -$178.7M | -$221.7M | -$285.3M | -$527.3M |
Cash Flow (Annual)
Last updated: Jul 5, 2026 4:11am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$48.8M | -$44.1M | -$40.4M | -$17.6M | -$30.2M |
| Capital Expenditure | -$1.3M | $-728,000 | $-398,000 | $-26,000 | $-128,000 |
| Free Cash Flow | -$50.1M | -$44.9M | -$40.8M | -$17.7M | -$30.4M |
| Acquisitions (net) | $0 | -$39.0M | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | -$2.6M | $-4,000 | $0 | $0 |
| Net Change in Cash | -$1.9M | -$8.4M | $11.6M | -$1.5M | $54.7M |
Analyst Estimates (Annual)
Last updated: Jul 5, 2026 4:11am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$869,250 $816,576 – $974,596
|
$869,250 $816,576 – $974,596
|
$869,250 $816,576 – $974,596
|
$5.0M $4.7M – $5.6M
|
| EBITDA |
$-173,849 $-194,919 – $-163,315
|
$-173,849 $-194,919 – $-163,315
|
$-173,849 $-194,919 – $-163,315
|
-$1.0M -$1.1M – $-942,315
|
| Net Income |
-$30.2M -$36.2M – -$24.3M
|
-$27.7M -$35.1M – -$20.2M
|
-$27.3M -$31.6M – -$25.1M
|
-$29.6M -$34.3M – -$27.3M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 5, 2026 4:11am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | -100.0% | — | -67.4% |
| Gross Profit Growth | +380.0% | -395.0% | +139.1% | -72.4% |
| Operating Income Growth | +18.5% | -3.2% | +44.2% | -64.8% |
| Net Income Growth | +31.4% | -19.5% | -47.7% | -280.8% |
| EBITDA Growth | +33.7% | -20.8% | -51.0% | -288.7% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-15 | Maleki Andrew Pedrum | A-Award | 607.00 | $19.01 | $11,539 |
| 2026-06-15 | Li Yang | A-Award | 1,666.00 | $8.11 | $13,511 |
| 2026-06-15 | Williams Charles O | A-Award | 1,666.00 | $8.11 | $13,511 |
| 2026-06-15 | Parker Craig C | A-Award | 1,622.00 | $8.11 | $13,154 |
| 2026-05-13 | Kutzkey Tim | A-Award | 5,550.00 | $30.14 | $167,277 |
| 2026-05-13 | Rothenberg Mace | A-Award | 5,550.00 | $30.14 | $167,277 |
| 2026-05-13 | WOODHOUSE DAVID J | A-Award | 5,550.00 | $30.14 | $167,277 |
| 2026-05-13 | Haak-Frendscho Mary | A-Award | 5,550.00 | $30.14 | $167,277 |
| 2026-05-13 | CHAI CHRISTOPHER Y | A-Award | 5,550.00 | $30.14 | $167,277 |
| 2026-05-13 | BJERKHOLT ERIC | A-Award | 5,550.00 | $30.14 | $167,277 |
| 2026-05-13 | Berkenblit Anna | A-Award | 5,550.00 | $30.14 | $167,277 |
| 2026-05-01 | Li Yang | M-Exempt | 4,375.00 | $0.00 | $0 |
| 2026-05-04 | Li Yang | S-Sale | 1,584.00 | $33.33 | $52,799 |
| 2026-05-01 | Li Yang | M-Exempt | 4,375.00 | $0.00 | $0 |
| 2026-05-01 | Williams Charles O | M-Exempt | 5,625.00 | $0.00 | $0 |
| 2026-05-04 | Williams Charles O | S-Sale | 2,036.00 | $33.33 | $67,866 |
| 2026-05-01 | Williams Charles O | M-Exempt | 5,625.00 | $0.00 | $0 |
| 2026-05-01 | Parker Craig C | M-Exempt | 12,500.00 | $0.00 | $0 |
| 2026-05-04 | Parker Craig C | S-Sale | 4,524.00 | $33.33 | $150,798 |
| 2026-05-01 | Parker Craig C | M-Exempt | 12,500.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for SRZN — it's generated by the pipeline (
market-narrative step).
No community reviews yet for SRZN.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.377 · 1648bd22 · 2026-07-04 14:36:23